Chris W. McAndrew
Partner
Christopher McAndrew is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati.
Prior to joining the firm, Chris was a postdoctoral fellow in Dr. Paul Goldsmith's laboratory at the National Institutes of Health in the National Cancer Institute, working under the Office of Science and Technology Partnerships division. In this role, he developed and evaluated next-generation antibody-based biomarker detection methods and systems for start-up biotech companies and in-house research; designed and purified antigens for antibody production in hosts; and screened antibodies for use in various methods and platforms. During his time at the National Institutes of Health, Chris also worked as an intern in the Office of Technology Transfer.
Previously, as a graduate student in the chemistry and biochemistry department at the University of California, San Diego, Chris studied the role of novel cyclin-like proteins in responses to DNA damage, as well as the crosstalk between the Fibroblast Growth Factor Receptor and the inflammatory response pathway. In addition, he worked as an intern at Tech Law performing patent and trademark due diligence.
Experience
Christopher McAndrew is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati.
Prior to joining the firm, Chris was a postdoctoral fellow in Dr. Paul Goldsmith's laboratory at the National Institutes of Health in the National Cancer Institute, working under the Office of Science and Technology Partnerships division. In this role, he developed and evaluated next-generation antibody-based biomarker detection methods and systems for start-up biotech companies and in-house research; designed and purified antigens for antibody production in hosts; and screened antibodies for use in various methods and platforms. During his time at the National Institutes of Health, Chris also worked as an intern in the Office of Technology Transfer.
Previously, as a graduate student in the chemistry and biochemistry department at the University of California, San Diego, Chris studied the role of novel cyclin-like proteins in responses to DNA damage, as well as the crosstalk between the Fibroblast Growth Factor Receptor and the inflammatory response pathway. In addition, he worked as an intern at Tech Law performing patent and trademark due diligence.
Education
- J.D., The George Washington University Law School, 2016
- Ph.D., Chemistry, University of California, San Diego, 2010Authored dissertation titled "Cell cycle and DNA damage response regulation by Spy1, and the intersection of FGFR and NFkappaB pathways"
- M.S., Chemistry, University of California, San Diego, 2007Participant, LEAN/Six Sigma Enterprise Certificate Program; Participant, FDA Regulatory Affairs Certificate Program; Recipient, Achievement Rewards for College Scientists Scholarship
- B.S., Biochemistry, University of Delaware, 2004Minors in Biological Sciences and Biomedical Engineering; Recipient, Howard Hughes Medical Institute Scholarship
Honors
- Named to the 2025 and 2026 Lawdragon “500 X – The Next Generation” lists
- Recipient, Postdoctoral Training Grant, National Institutes of Health
- Recipient, Federal Technology Transfer Award, National Institutes of Health
Admissions
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., The George Washington University Law School, 2016
- Ph.D., Chemistry, University of California, San Diego, 2010Authored dissertation titled "Cell cycle and DNA damage response regulation by Spy1, and the intersection of FGFR and NFkappaB pathways"
- M.S., Chemistry, University of California, San Diego, 2007Participant, LEAN/Six Sigma Enterprise Certificate Program; Participant, FDA Regulatory Affairs Certificate Program; Recipient, Achievement Rewards for College Scientists Scholarship
- B.S., Biochemistry, University of Delaware, 2004Minors in Biological Sciences and Biomedical Engineering; Recipient, Howard Hughes Medical Institute Scholarship
Honors
- Named to the 2025 and 2026 Lawdragon “500 X – The Next Generation” lists
- Recipient, Postdoctoral Training Grant, National Institutes of Health
- Recipient, Federal Technology Transfer Award, National Institutes of Health
Admissions
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
Select Publications
- Co-author with D. Hoffmeister, V. Norviel, P. Girinath, and C. Andres, "FDA Developments in 2015 and What's to Come in 2016," Law360, January 11, 2016
- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
- Co-author with V. Norviel, E. Kepplinger, J. Chambers, and L. Lieto, "Strategies for Maximizing Patent Claim Scope and Patent Prosecution for Diagnostic Method Claims in the Wake of Mayo v. Prometheus," The Life Sciences Report, Spring 2013
- Co-author with A.N. Meyer, K.A. Drafahl, J.E. Gilda, L.H Gallo, M. Haas, L.M. Brill, and D.J Donoghue, "Tyrosine phosphorylation allows integration of multiple signaling inputs by IKKβ," PLoS One, 2013
- Co-author with L. Boeckmann, Y. Takahashi, W.C. Au, P.K. Mishra, J.S. Choy, A.R. Dawson, M.Y. Szeto, T.J. Waybright, C.D. Heger, P.K Goldsmith, T.D. Veenstra, R.E. Baker RE, and M.A. Basrai, "Phosphorylation of centromeric histone H3 variant regulates chromosome segregation in Saccharomyces cerevisiae," Molecular Biology of the Cell, 2013
- Co-author with J.M. Fleming, E. Ginsburg, C.D. Heger, L. Cheston, J. Rodriguez-Canales, B.K. Vonderhaar, and P.K. Goldsmith, "Characterization of △7/11, a functional prolactin-binding protein," Journal of Molecular Endocrinology, 2012
- Co-author with K.A. Drafahl, A.N. Meyer, and D.J. Donoghue, "The Receptor Tyrosine Kinase FGFR4 Regulates NF-kappaB Signaling," PLoS One, 2010
- Co-author with R.F. Gastwirt and D.J. Donoghue, "The Atypical CDK Activator Spy1 Regulates the Intrinsic DNA Damage Response and Is Dependent upon p53 to Inhibit Apoptosis," Cell Cycle, 2009
- Co-author with K.A. Drafahl and D.J. Donoghue, Signaling from FGF Receptors in Development and Disease, Humana Press, 2008
- Co-author with A.N. Meyer and D.J. Donoghue, "NDGA Inhibits an FGFR3 Mutant and Blocks Downstream Signaling in Multiple Myeloma Cells," Cancer Research, 2008
- Co-author with R.F. Gastwirt and D.J. Donoghue, "Regulation of the Cell Cycle," Wiley Encyclopedia of Chemical Biology, John Wiley & Sons, 2008
- Co-author with R.F. Gastwirt and D.J. Donoghue, "Speedy/RINGO Regulation of CDKs in Cell Cycle, Checkpoint Activation and Apoptosis," Cell Cycle, 2007
- Co-author with R.F. Gastwirt, A.N. Meyer, L.A. Porter, and D.J. Donoghue, "Spy1 Enhances Phosphorylation and Degradation of the Cell Cycle Inhibitor," Cell Cycle, 2007
- Co-author with R.F. Gastwirt RF, D.A. Slavin, and D.J. Donoghue, "Spy1 Expression Prevents Normal Cellular Responses to DNA Damage: Inhibition of Apoptosis and Checkpoint Activation," Journal of Biology and Chemistry, 2006
- Co-author with D.T. Yeung, D. Josse, J.D. Nicholson, B.J. Bahnson, D.E. Lenz, and D.M. Cerasoli, "Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model," Biochimica et Biophysica Acta, 2004
Insights
Select Publications
- Co-author with D. Hoffmeister, V. Norviel, P. Girinath, and C. Andres, "FDA Developments in 2015 and What's to Come in 2016," Law360, January 11, 2016
- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
- Co-author with V. Norviel, E. Kepplinger, J. Chambers, and L. Lieto, "Strategies for Maximizing Patent Claim Scope and Patent Prosecution for Diagnostic Method Claims in the Wake of Mayo v. Prometheus," The Life Sciences Report, Spring 2013
- Co-author with A.N. Meyer, K.A. Drafahl, J.E. Gilda, L.H Gallo, M. Haas, L.M. Brill, and D.J Donoghue, "Tyrosine phosphorylation allows integration of multiple signaling inputs by IKKβ," PLoS One, 2013
- Co-author with L. Boeckmann, Y. Takahashi, W.C. Au, P.K. Mishra, J.S. Choy, A.R. Dawson, M.Y. Szeto, T.J. Waybright, C.D. Heger, P.K Goldsmith, T.D. Veenstra, R.E. Baker RE, and M.A. Basrai, "Phosphorylation of centromeric histone H3 variant regulates chromosome segregation in Saccharomyces cerevisiae," Molecular Biology of the Cell, 2013
- Co-author with J.M. Fleming, E. Ginsburg, C.D. Heger, L. Cheston, J. Rodriguez-Canales, B.K. Vonderhaar, and P.K. Goldsmith, "Characterization of △7/11, a functional prolactin-binding protein," Journal of Molecular Endocrinology, 2012
- Co-author with K.A. Drafahl, A.N. Meyer, and D.J. Donoghue, "The Receptor Tyrosine Kinase FGFR4 Regulates NF-kappaB Signaling," PLoS One, 2010
- Co-author with R.F. Gastwirt and D.J. Donoghue, "The Atypical CDK Activator Spy1 Regulates the Intrinsic DNA Damage Response and Is Dependent upon p53 to Inhibit Apoptosis," Cell Cycle, 2009
- Co-author with K.A. Drafahl and D.J. Donoghue, Signaling from FGF Receptors in Development and Disease, Humana Press, 2008
- Co-author with A.N. Meyer and D.J. Donoghue, "NDGA Inhibits an FGFR3 Mutant and Blocks Downstream Signaling in Multiple Myeloma Cells," Cancer Research, 2008
- Co-author with R.F. Gastwirt and D.J. Donoghue, "Regulation of the Cell Cycle," Wiley Encyclopedia of Chemical Biology, John Wiley & Sons, 2008
- Co-author with R.F. Gastwirt and D.J. Donoghue, "Speedy/RINGO Regulation of CDKs in Cell Cycle, Checkpoint Activation and Apoptosis," Cell Cycle, 2007
- Co-author with R.F. Gastwirt, A.N. Meyer, L.A. Porter, and D.J. Donoghue, "Spy1 Enhances Phosphorylation and Degradation of the Cell Cycle Inhibitor," Cell Cycle, 2007
- Co-author with R.F. Gastwirt RF, D.A. Slavin, and D.J. Donoghue, "Spy1 Expression Prevents Normal Cellular Responses to DNA Damage: Inhibition of Apoptosis and Checkpoint Activation," Journal of Biology and Chemistry, 2006
- Co-author with D.T. Yeung, D. Josse, J.D. Nicholson, B.J. Bahnson, D.E. Lenz, and D.M. Cerasoli, "Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model," Biochimica et Biophysica Acta, 2004
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemical assays
- Biochemistry
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Glycobiology
- Host-pathogen interactions
- Immuno-oncology
- Immunobiology
- Immunology
- MicroRNA (miRNA) research
- Molecular biology
- Neurobiology
- Proteomics
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology
Therapeutics and Drug Discovery
- Biosimilars
- CRISPR
- Drug conjugates
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets
- Peptide therapeutics
- Pharmacodynamics
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- RNA interference (RNAi)
- Vaccines
Diagnostics and Medical Devices
- Bioinformatic
- Diagnostics
- Point-of-care testing (POCT)
Chemistry and Material Science
- Peptidomimetics
- Protein engineering
- Protein folding
Engineering and Technology
- Machine learning
- Microfluidics
Genomics and Data Analysis
- Bioinformatics algorithms
- Computational biology
- Sequencing
- Single-cell sequencing
Miscellaneous
- Cancer
- COVID 19
- Formulations
- Infectious diseases
Technical Fluency
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemical assays
- Biochemistry
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Glycobiology
- Host-pathogen interactions
- Immuno-oncology
- Immunobiology
- Immunology
- MicroRNA (miRNA) research
- Molecular biology
- Neurobiology
- Proteomics
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology
Therapeutics and Drug Discovery
- Biosimilars
- CRISPR
- Drug conjugates
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets
- Peptide therapeutics
- Pharmacodynamics
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- RNA interference (RNAi)
- Vaccines
Diagnostics and Medical Devices
- Bioinformatic
- Diagnostics
- Point-of-care testing (POCT)
Chemistry and Material Science
- Peptidomimetics
- Protein engineering
- Protein folding
Engineering and Technology
- Machine learning
- Microfluidics
Genomics and Data Analysis
- Bioinformatics algorithms
- Computational biology
- Sequencing
- Single-cell sequencing
Miscellaneous
- Cancer
- COVID 19
- Formulations
- Infectious diseases
Recent Insights
News Articles
Wilson Sonsini Attorneys Named to Lawdragon’s 2026 List of Next-Generation Lawyers
Ten Wilson Sonsini attorneys have been recognized in the 2026 edition of Lawdragon 500 X – The Next Generation. Individuals listed in the guide are “the future of the law” and are recognized for their accomplishments in their career thus far.
Learn More
News Articles
Lawdragon Names 12 Wilson Sonsini Lawyers to Its 2025 List of Next-Generation Lawyers
Twelve Wilson Sonsini attorneys have been recognized in the 2025 Lawdragon 500 X – The Next Generation, the third edition of the guide. Individuals listed in the guide traditionally have “proven themselves early in private practice, accruing credentials, deals, and cases early and often,” with the majority of lawyers having been in practice between seven and fifteen years.
Learn More
Recent Events
Affiliated Programs
MassBio Drive Fall 2026
Wilson Sonsini is proud to partner with MassBio to help empower the next generation of tech bio innovators through Drive. This accelerator equips early-stage companies with the business curriculum, mentorship, and industry connections needed to help breakthrough science move faster and further.
Learn More
Speaking Engagements
NHS Clinical Entrepreneur Programme Big Pitch 2025
This annual Big Pitch event marks the commencement off the new cohort of the NHS Clinical Entrepreneur Programme and celebrates the remarkable achievements of our current Clinical Entrepreneurs. The event will feature main stage keynotes from senior DHSC and NHS leaders, partner panels, pitches from our entrepreneurs and an exhibition zone showcasing innovations from Clinical Entrepreneurs, innovators from other NHSE programmes and CEP partners. There will also be a range of expert satellite sessions and the opportunity to meet the CEP mentors.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.